Citius Non Current Liabilities Total vs Common Stock Shares Outstanding Analysis
| CTOR Stock | 0.94 0.06 6.00% |
Citius Oncology, financial indicator trend analysis is way more than just evaluating Citius Oncology, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Citius Oncology, is a good investment. Please check the relationship between Citius Oncology, Non Current Liabilities Total and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Oncology,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Citius Stock, please use our How to Invest in Citius Oncology, guide.
Non Current Liabilities Total vs Common Stock Shares Outstanding
Non Current Liabilities Total vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Citius Oncology, Non Current Liabilities Total account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Citius Oncology,'s Non Current Liabilities Total and Common Stock Shares Outstanding is -0.6. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Citius Oncology,, assuming nothing else is changed. The correlation between historical values of Citius Oncology,'s Non Current Liabilities Total and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Citius Oncology, are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Current Liabilities Total i.e., Citius Oncology,'s Non Current Liabilities Total and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.6 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Non Current Liabilities Total
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Citius Oncology,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Citius Oncology, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Oncology,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Citius Stock, please use our How to Invest in Citius Oncology, guide.As of 11/28/2024, Tax Provision is likely to drop to about 460.8 K. In addition to that, Selling General Administrative is likely to drop to about 5.1 M
| 2010 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.9M | 12.1M | 13.9M | 9.3M | Research Development | 3.4M | 4.2M | 4.9M | 4.2M |
Citius Oncology, fundamental ratios Correlations
Click cells to compare fundamentals
Citius Oncology, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.76 | ESPR | Esperion Therapeutics | PairCorr |
| 0.69 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.58 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.